Acne News and Research

Latest Acne News and Research

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

7 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Twelve residents receive one-year fellowship grant to study medical dermatology

Twelve dermatology residents from leading medical schools around the country each received a $40,000, one-year fellowship grant to study medical dermatology. The fellowships, awarded by the National Psoriasis Foundation, provide support to eligible institutions to develop and enhance opportunities for physicians training for careers in medical dermatology.

1 Jul 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Health Canada approves Solta Medical's Thermage CPT, Fraxel re:store Dual systems

Solta Medical, Inc., the pioneer in fractional resurfacing and non-invasive skin tightening and a market leader in aesthetic skin treatments, today announced Health Canada approval of its Thermage CPT™ and Fraxel re:store® Dual systems. These products are now available to physicians in Canada. In the fall of 2009, the company received U.S. FDA clearance to market and sell both the Thermage CPT and Fraxel re:store Dual systems. Both systems are now available in over 100 countries worldwide.

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

18 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Solta Medical on list of preliminary additions to Russell indexes

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has been included on the list of preliminary additions to the Russell 3000® Index and the Russell Global® Index posted by Russell Investments on June 11, 2010 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010. All Russell indexes are subindexes of the Global Index.

14 Jun 2010

Onset Therapeutics expands sales force by over 50% in 2010

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced the completion of the Company's latest sales force expansion initiative designed to provide national dermatology coverage to support the success of two recently launched products and the Company's rapidly growing pipeline of products in various stages of development.

10 Jun 2010

NexGen Biomedical offers RNAi / PSR platform technology for sale

NexGen Biomedical, Inc. announced today that it is offering its RNAi / PSR platform technology for sale. "While technologies like siRNA are well suited for disease conditions involving expression of a single protein, the RNAi / PSR technology is better suited for conditions involving expression of a broad spectrum of proteins such as happens with cell hyperproliferation, inflammation, and viral infections.

8 Jun 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex, Inc. announced today that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity® excimer laser in the treatment of generalized psoriasis when used in combination with Clobex® spray. Dr. Koo is Professor and Vice Chairman in the Department of Dermatology at the University of California San Francisco Medical Center. Spearheading the study will be Dr. Koo's colleague, Tina Bhutani, MD.

8 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant.

31 May 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the first quarter of 2010. Management is working diligently to finalize the amended Annual Report on Form 10-K for 2009.

18 May 2010

EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, successfully launched its products in the USA. EvoLife Laboratories is present at the annual Oncology Nursing Society Congress 2010 in San Diego and utilizes this opportunity to further engage with nurses and caregivers.

15 May 2010

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).

13 May 2010

Acne News and Research

Latest Acne News and Research

FDA grants Fougera first generic approval for Adapalene Cream 0.1%

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Twelve residents receive one-year fellowship grant to study medical dermatology

Vicept completes $16 million Series A financing

Health Canada approves Solta Medical's Thermage CPT, Fraxel re:store Dual systems

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Solta Medical on list of preliminary additions to Russell indexes

Onset Therapeutics expands sales force by over 50% in 2010

NexGen Biomedical offers RNAi / PSR platform technology for sale

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

China Sky One Medical first-quarter total revenues increase 16.4% to $28.9 million

EvoLife Laboratories participates in ONS Congress 2010 to assist nurses, caregivers

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Acne News and Research

Latest Acne News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in